NIKI
Niki BioSolutions, Inc. (NIKI)
Healthcare • NASDAQ • $1.83-5.67%
- Symbol
- NIKI
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $1.83
- Daily Change
- -5.67%
- Market Cap
- $6.33M
- Trailing P/E
- N/A
- Forward P/E
- N/A
- 52W High
- $17.20
- 52W Low
- $1.94
- Analyst Target
- N/A
- Dividend Yield
- 0.00%
- Beta
- -1.00
Niki BioSolutions, Inc., through its subsidiaries, operates as a clinical-stage biopharmaceutical company and engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in a Phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in a Phase 1 clinical trial for the treatment of bacterial infections, such as staphylococcus aureus, mycobacterium tuberculosis, and pseudomonas aeruginosa. The company also develops SACT-COV19, a repurposed small molecule, which is in a preclinical trial for the treatment of coronavirus disease; SACT-2 and SACT-3; ALS-1, a small molecule, which is in a preclinic…
Company websiteResearch NIKI on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.